파나마 - 영어 - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

shandong luoxin pharmaceutical group stock co.,ltd - cefotaxima (sÓdica) - cefotaxima (sÓdica)....1.0 g.

파나마 - 영어 - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

reyoung pharmaceutical co., ltd - cefotaxima (sÓdica) - cefotaxima (sÓdica)....1.00 g

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefotaxime sodium 1.048 g equivalent to 1 g cefotaxime;  ;   - powder for injection - 1 g - active: cefotaxime sodium 1.048 g equivalent to 1 g cefotaxime     - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefotaxime sodium 2.096 g equivalent to 2 g cefotaxime;  ;   - powder for injection - 2 g - active: cefotaxime sodium 2.096 g equivalent to 2 g cefotaxime     - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cefotaxime sodium 525mg equivalent to 500 mg cefotaxime;  ;   - powder for injection - 500 mg - active: cefotaxime sodium 525mg equivalent to 500 mg cefotaxime     - dbl™ cefotaxime sodium for injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemia. respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft tissue infections: cellulitis, peritonitis and wound infections. bone and joint infections: osteomyelitis, septic arthritis. obstetric and gynaecological infections: pelvic inflammatory disease. gonorrhoea: particularly if penicillin-resistant. other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of dbl™ cefotaxime sodium for injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. dbl™ cefotaxime sodium for injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

몰타 - 영어 - Malta Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - cefotaxime - powder for solution for infusion or injection - cefotaxime 1 g - antibacterials for systemic use

몰타 - 영어 - Malta Medicines Authority

wockhardt uk limited - cefotaxime sodium - powder for solution for infusion or injection - cefotaxime sodium 2 g - antibacterials for systemic use

몰타 - 영어 - Malta Medicines Authority

villerton invest s.a. - cefotaxime sodium - powder for solution for infusion or injection - cefotaxime sodium 500 mg - antibacterials for systemic use

몰타 - 영어 - Malta Medicines Authority

villerton invest s.a. - cefotaxime sodium - powder for solution for infusion or injection - cefotaxime sodium 1 g - antibacterials for systemic use

몰타 - 영어 - Malta Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - cefotaxime - powder for solution for injection/infusion - cefotaxime 1 g - antibacterials for systemic use